Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC) Meeting Abstract
| Authors: | Oh, D. Y.; Ajani, J. A.; Bang, Y. J.; Chung, H. C.; Lacy, J.; Lee, J.; Macarulla, T.; Manji, G. A.; O'Reilly, E. M.; Allen, S.; Al-Sakaff, N. J. A.; Barak, H.; Patel, J.; Pintoffl, J. P.; Shemesh, C.; Zhang, W.; Zhang, X.; Chau, I. |
| Abstract Title: | Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC) |
| Meeting Title: | 2020 Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2020 Jan 23-25 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-02-01 |
| Language: | English |
| ACCESSION: | WOS:000530922700686 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.4_suppl.712 |
| Notes: | Meeting Abstract: 712 -- Source: Wos |
